Correlation Between Seres Therapeutics and Structure Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Seres Therapeutics and Structure Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Seres Therapeutics and Structure Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Seres Therapeutics and Structure Therapeutics American, you can compare the effects of market volatilities on Seres Therapeutics and Structure Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Seres Therapeutics with a short position of Structure Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Seres Therapeutics and Structure Therapeutics.

Diversification Opportunities for Seres Therapeutics and Structure Therapeutics

-0.76
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Seres and Structure is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Seres Therapeutics and Structure Therapeutics America in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Structure Therapeutics and Seres Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Seres Therapeutics are associated (or correlated) with Structure Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Structure Therapeutics has no effect on the direction of Seres Therapeutics i.e., Seres Therapeutics and Structure Therapeutics go up and down completely randomly.

Pair Corralation between Seres Therapeutics and Structure Therapeutics

Given the investment horizon of 90 days Seres Therapeutics is expected to generate 2.15 times more return on investment than Structure Therapeutics. However, Seres Therapeutics is 2.15 times more volatile than Structure Therapeutics American. It trades about 0.27 of its potential returns per unit of risk. Structure Therapeutics American is currently generating about -0.08 per unit of risk. If you would invest  723.00  in Seres Therapeutics on May 26, 2025 and sell it today you would earn a total of  1,221  from holding Seres Therapeutics or generate 168.88% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Seres Therapeutics  vs.  Structure Therapeutics America

 Performance 
       Timeline  
Seres Therapeutics 

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Seres Therapeutics are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Seres Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.
Structure Therapeutics 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Structure Therapeutics American has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in September 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Seres Therapeutics and Structure Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Seres Therapeutics and Structure Therapeutics

The main advantage of trading using opposite Seres Therapeutics and Structure Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Seres Therapeutics position performs unexpectedly, Structure Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will offset losses from the drop in Structure Therapeutics' long position.
The idea behind Seres Therapeutics and Structure Therapeutics American pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance